""Is KG really cutting's its bovine thrombin price by 30% for multi year contracts? What I heard before was a 10-15% reduction in price.
Kevin DeGeeter, an analyst at Oppenheimer & Co., said, there were signs that King Pharmaceuticals was aggressively cutting the price of its product.""
imo,,,,Hospitals should interpret the above as a big, big, big red flag against KG bovine thrombin.